Every material Form 8-K Kura Oncology, Inc. has filed with the SEC since August 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Kura Oncology formed a wholly owned subsidiary, Caspian Therapeutics, to develop next-generation menin inhibitors for diabetes and other cardiometabolic diseases. On September 8, 2026, Caspian completed a $50.0 million Series A preferred stock financing, in which Kura invested $4.3 million and which left Kura holding about 49.2% of Caspian's outstanding capital stock.
Caspian completed a $50.0 million private Series A preferred stock financing on September 8, 2026.
Kura invested $4.3 million and held about 49.2% of Caspian's outstanding capital stock after the financing.
Kura contributed rights to menin inhibitors, including KO-7246, to Caspian for Caspian common stock and reimbursement of up to $1.5 million in maintenance costs.
Kura will provide research, development and administrative services to Caspian under a services agreement with a one-year initial term.
Kura Oncology appointed Jennifer Fulk as Chief Financial Officer, principal financial officer and principal accounting officer, effective September 8, 2026, replacing Troy E. Wilson and Thomas Doyle in those roles. The filing sets out her $550,000 base salary, an option for 450,000 shares and a performance-based restricted stock unit award covering 173,438 shares, which tie her pay to the company's financial position and development progress.
Jennifer Fulk appointed CFO effective September 8, 2026, replacing Troy E. Wilson in the CFO role and Thomas Doyle as principal accounting officer
Annual base salary of $550,000 and discretionary bonus of up to 45% of base salary
Option to purchase 450,000 shares, vesting over four years, plus a performance-based RSU award covering 173,438 shares
Prior roles include CFO of Soleno Therapeutics (March 2026 to May 2026) and CFO of Talkspace, Inc. (July 2021 to May 2024)
Kura Oncology reported second quarter 2026 results, its second full quarter of KOMZIFTI sales. Total revenue rose to $20.9 million from $15.3 million a year earlier, but the net loss widened to $68.3 million, or $0.77 per share, from $66.1 million, or $0.75 per share. Cash, cash equivalents and short-term investments fell to $519.0 million at June 30, 2026, from $667.2 million at December 31, 2025, and the company cites $180 million in expected collaboration payments from Kyowa Kirin.
Net product revenue was $9.1 million, compared with none in 2Q 2025; new patient starts were about 115, up 35% from 1Q 2026.
Collaboration revenue fell to $11.8 million from $15.3 million in 2Q 2025.
Net loss was $68.3 million, or $0.77 per share, versus $66.1 million, or $0.75 per share, a year earlier.
Cash and short-term investments were $519.0 million at June 30, 2026, plus $180 million in anticipated Kyowa Kirin collaboration payments.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Kura Oncology, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →